Adroitec Information Systems Pvt. Ltd. leads the charge in additive manufacturing, consistently redefining the potential of 3D printing with bespoke solutions tailored to diverse industries. With over three decades of expertise, the company seamlessly fuses traditional engineering foundations with groundbreaking advancements in additive manufacturing and smart engineering techniques. This blend of innovation and legacy positions Adroitec as a bridge between the past’s pioneering ideas and the future’s transformative possibilities.
Partnering with globally renowned industry leaders, Adroitec excels in cutting-edge 3D printing technologies, including Fused Deposition Modeling, Stereolithography, and Direct Metal Laser Sintering. By continuously pushing boundaries, the company sets new benchmarks and reshapes the industry landscape.
Adroitec’s extensive capabilities span CAD, Reverse Engineering, Concept Design, 3D Printing, Tooling, and Digital Creation. These end-to-end solutions empower clients to excel in research and development, accelerate rapid prototyping, and execute customized engineering projects. The company’s innovative technologies enhance productivity, shorten development cycles, and drive the adoption of smart engineering practices. In doing so, Adroitec fuels its clients’ growth, helping them achieve their strategic business objectives.
In an exclusive conversation with The Interview World, Saroop Chand, Founder and Director of Adroitec, delves into the company’s trailblazing work. He discusses the design of industry-specific 3D printing machines, explores the use of biomaterials for creating human body parts, and explains the mechanisms behind printing personalized medicines. Chand also highlights the immense opportunities unfolding in the world of 3D printing. Here are the most compelling insights from his visionary conversation.
Q: What innovations is Adroitec bringing to 3D printing, and how are these addressing the specific challenges different sectors face?
A: Adroitec began its journey as a company focused on computer-aided design (CAD) and computer-aided manufacturing (CAM). Through extensive interactions with R&D experts, we gained deep insights into design processes and the challenges of transforming concepts into manufactured products. Recognizing the need for improvement, we identified 3D printing as a game-changing tool. Unlike traditional methods, 3D printing eliminates the need for high capital investments while enabling rapid production of parts at significantly lower costs.
Building on this realization, we expanded our offerings to include 3D printing services. Today, we have taken this innovation further by developing our 3D printers tailored to the needs of various industries. Until recently, most 3D printers were imported, but through strategic technology transfer agreements with the Department of Atomic Energy and other agencies, we have designed and produced printers locally.
A key element of 3D printing is the input material, which determines the final product’s functionality. At Adroitec, we work with a wide range of materials to ensure the creation of realistic, functional parts—not just prototypes. This focus on material innovation allows us to deliver solutions that meet the evolving demands of industries while driving greater efficiency and effectiveness.
Q: What types of biomaterials does Adroitec use in designing healthcare products, and how are they tailored to meet specific needs?
A: We work with a diverse range of materials, starting with silicon and extending to advanced bio-inks and biocompatible materials. For instance, titanium, widely used for implants, gains enhanced effectiveness when coated with tantalum. Our focus lies in adapting these materials to suit 3D printing processes, enabling their application in critical areas such as implants and anatomical models.
By leveraging these materials, we create true-to-life anatomical models, develop comprehensive training kits, and support precise surgical planning. This integration of material science and 3D printing technology drives innovation and improves outcomes in medical and surgical applications.
Q: What factors do you consider when designing biomaterial-based body parts, like kidney or heart tissues, for seamless integration?
A: Soft tissues serve a range of essential functions that extend beyond their biomechanical role. They produce various chemicals and hormones, contributing to complex bodily processes. Currently, there is no single ink capable of producing fully functional tissue parts on a global scale. However, 3D printing has made significant strides in the field of anatomical support, especially in creating orthopedic and prosthetic components, as well as devices that aid in immobilization. For instance, during the COVID-19 pandemic, 3D printing played a critical role in developing nasal phalanges.
Research into bio-inks is ongoing, with the aim of enabling tissue development. This involves specialized bioprinters, which we design and manufacture. In India alone, around 15 institutes are conducting pioneering work with bio-inks, experimenting with combinations of collagen, proteins, and other materials to replicate the properties of natural tissues. This research is essential for advancing the creation of bio-printed parts.
Another promising application of 3D printing lies in the customization of medicines. Bioprinters are increasingly proving their value in producing patient-specific medications, revolutionizing personalized healthcare solutions.
Q: Could you elaborate on your advancements in personalized medicine and the steps taken so far in customizing treatments for patients?
A: We have developed a printer that enables the production of personalized medicine, which can be encapsulated for patient use. This device is capable of creating multiple capsules, each containing specific chemicals, medicines, or base formulations. Through a layer-by-layer approach, it constructs personalized medication tailored to individual needs.
With this innovation, patients no longer need to manage complex regimens of 20 different medicines, where forgetting doses is common. Instead, personalized medicine allows precise dosages, such as 3 milligrams or 7 milligrams, to be delivered in the correct proportions. This ensures more accurate and convenient medication administration, significantly improving patient compliance and treatment effectiveness.
Q: How do the costs of these personalized medicines compare to bulk-produced medicines available in the market?
A: The process incurs no additional costs beyond the basic formulation, as the primary expense is associated with 3D printing. Once we develop the molds, you can use them to create capsules and fill them with biomedicines. This approach avoids extra expenses, with the only costs being those of the initial formulation.
Q: What market opportunities do you envision for the medical-centric 3D printers you are developing?
A: Currently, more than 50 such 3D printers are in operation. Significant implementation has happened, particularly in the field of implants, including dental, knee, hip, and shoulder implants. In India, nearly 5,000 customized implants are manufactured daily using 3D printing technology. Opportunities are undoubtedly huge.
